CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 6 enrolled
Drug / intervention
Pimavanserindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04188392
NCT04188392Phase 4Completed
CompareCT.gov

Pilot Feasibility Study of Pimavanserin for Insomnia in Veterans With Posttraumatic Stress Disorder

Baylor College of Medicine·interventional·Posted Dec 5, 2019·Updated Aug 31, 2022

In Brief

A Phase 4 clinical trial evaluating Pimavanserin for Post-traumatic Stress Disorder and Insomnia. Completed, enrolled 6 participants across 1 site.

Detailed Summary

This preliminary, open-label study assesses the feasibility of 34mg at bedtime for 6 weeks in Veterans with Posttraumatic Stress Disorder and insomnia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost-traumatic Stress Disorder, Insomnia
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedDec 5, 2019
Enrollment StartJan 6, 2020
Primary CompletionOct 27, 2021
Study CompletionNov 10, 2021
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 6.6 years ago

Interventions

Pimavanserindrug

pimavanserin tablet